2018 旭硝子財団 助成研究発表会 要旨集

89/198

2. sp3 CH 3sp3 (X=counterion)YRORxanthenederivertivesbenzylicheteroarylationLewisAcid(Y=O,S)ArIHetArXHetArHr.t.HetArHArI(OAc)2/HX 3. sp3 sp3 sp3 MoriartyPhIO/BF3 sp3 -oxo PIFA dimerTMSOTf73%85%4Michael 4. sp3 3. sp3 8,9) 4. (1) Recent account: Curr. Org. Chem.2016,20, 580 (Coupling Special Issue). (2) Angew. Chem., Int. Ed.2010,49, 3334; Chem.-Eur. J.,2013,19, 15004 (highlighted in the journal). (3) Angew. Chem., Int. Ed.2011,50, 3785; Chem. Commun.2010,46, 7697 (Hot Articles). (4) Beilstein J. Org. Chem.2018, 14, 1087. (5) Tetrahedron2010,66, 5775 (Most Cited Articles in 2011); Heterocycles2018,97, in press (Kiyoshi Tomioka’s Special Issue). (6) Adv. Synth. Catal.2017,359, 3503. (7) Heterocycles2017,95, 1272 (Masakatsu Shibasaki’s Special Issue). (8) Angew. Chem. Int. Ed.2008,47, 3787; J. Am. Chem. Soc.2013,135, 4558 (Featured in Synfact,2013, 550.). (9) J. Org. Chem. 2017,82, 11954 (Hypervalent Iodine Special Issue); Org. Lett.2017,19, 4102. 5. 525-85771-1-1 077-561-4908E-mail: td1203@ph.ritsumei.ac.jp HP: http://www.ritsumei.ac.jp/pharmacy/dohi/ －81－